Literature DB >> 18922980

Induction of antiproliferative connective tissue growth factor expression in Wilms' tumor cells by sphingosine-1-phosphate receptor 2.

Mei-Hong Li1, Teresa Sanchez, Anna Pappalardo, Kevin R Lynch, Timothy Hla, Fernando Ferrer.   

Abstract

Connective tissue growth factor (CTGF), a member of the CCN family of secreted matricellular proteins, regulates fibrosis, angiogenesis, cell proliferation, apoptosis, tumor growth, and metastasis. However, the role of CTGF and its regulation mechanism in Wilms' tumor remains largely unknown. We found that the bioactive lipid sphingosine-1-phosphate (S1P) induced CTGF expression in a concentration- and time-dependent manner in a Wilms' tumor cell line (WiT49), whereas FTY720-phosphate, an S1P analogue that binds all S1P receptors except S1P2, did not. Further, the specific S1P2 antagonist JTE-013 completely inhibited S1P-induced CTGF expression, whereas the S1P1 antagonist VPC44116 did not, indicating that this effect was mediated by S1P2. This was confirmed by adenoviral transduction of S1P2 in WiT49 cells, which showed that overexpression of S1P2 increased the expression of CTGF. Induction of CTGF by S1P was sensitive to ROCK inhibitor Y-27632 and c-Jun NH2-terminal kinase inhibitor SP600125, suggesting the requirement of RhoA/ROCK and c-Jun NH2-terminal kinase pathways for S1P-induced CTGF expression. Interestingly, the expression levels of CTGF were decreased in 8 of 10 Wilms' tumor tissues compared with matched normal tissues by quantitative real-time PCR and Western blot analysis. In vitro, human recombinant CTGF significantly inhibited the proliferation of WiT49 cells. In addition, overexpression of CTGF resulted in significant inhibition of WiT49 cell growth. Taken together, these data suggest that CTGF protein induced by S1P2 might act as a growth inhibitor in Wilms' tumor.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18922980      PMCID: PMC2659653          DOI: 10.1158/1541-7786.MCR-07-2048

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  50 in total

1.  Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists.

Authors:  Suzanne Mandala; Richard Hajdu; James Bergstrom; Elizabeth Quackenbush; Jenny Xie; James Milligan; Rosemary Thornton; Gan-Ju Shei; Deborah Card; CarolAnn Keohane; Mark Rosenbach; Jeffrey Hale; Christopher L Lynch; Kathleen Rupprecht; William Parsons; Hugh Rosen
Journal:  Science       Date:  2002-03-28       Impact factor: 47.728

2.  Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization.

Authors:  Kenneth LaMontagne; Amanda Littlewood-Evans; Christian Schnell; Terence O'Reilly; Lorenza Wyder; Teresa Sanchez; Beatrice Probst; Jeannene Butler; Alexander Wood; Gene Liau; Eric Billy; Andreas Theuer; Timothy Hla; Jeanette Wood
Journal:  Cancer Res       Date:  2006-01-01       Impact factor: 12.701

3.  Elevated levels of connective tissue growth factor, WISP-1, and CYR61 in primary breast cancers associated with more advanced features.

Authors:  D Xie; K Nakachi; H Wang; R Elashoff; H P Koeffler
Journal:  Cancer Res       Date:  2001-12-15       Impact factor: 12.701

4.  CTGF/Hcs24 induces chondrocyte differentiation through a p38 mitogen-activated protein kinase (p38MAPK), and proliferation through a p44/42 MAPK/extracellular-signal regulated kinase (ERK).

Authors:  G Yosimichi; T Nakanishi; T Nishida; T Hattori; T Takano-Yamamoto; M Takigawa
Journal:  Eur J Biochem       Date:  2001-12

5.  Connective tissue growth factor is secreted through the Golgi and is degraded in the endosome.

Authors:  Y Chen; P Segarini; F Raoufi; D Bradham; A Leask
Journal:  Exp Cell Res       Date:  2001-11-15       Impact factor: 3.905

Review 6.  Transforming growth factor-beta and connective tissue growth factor: key cytokines in scleroderma pathogenesis.

Authors:  C P Denton; D J Abraham
Journal:  Curr Opin Rheumatol       Date:  2001-11       Impact factor: 5.006

7.  Expression of connective tissue growth factor in cartilaginous tumors.

Authors:  T Shakunaga; T Ozaki; N Ohara; K Asaumi; T Doi; K Nishida; A Kawai; T Nakanishi; M Takigawa; H Inoue
Journal:  Cancer       Date:  2000-10-01       Impact factor: 6.860

Review 8.  Connective tissue growth factor: potential role in glomerulosclerosis and tubulointerstitial fibrosis.

Authors:  S Gupta; M R Clarkson; J Duggan; H R Brady
Journal:  Kidney Int       Date:  2000-10       Impact factor: 10.612

9.  Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation.

Authors:  Y Liu; R Wada; T Yamashita; Y Mi; C X Deng; J P Hobson; H M Rosenfeldt; V E Nava; S S Chae; M J Lee; C H Liu; T Hla; S Spiegel; R L Proia
Journal:  J Clin Invest       Date:  2000-10       Impact factor: 14.808

Review 10.  Connective tissue growth factor: a new and important player in the pathogenesis of fibrosis.

Authors:  Andrew Leask; Alan Holmes; David J Abraham
Journal:  Curr Rheumatol Rep       Date:  2002-04       Impact factor: 4.592

View more
  32 in total

Review 1.  Sphingolipids and expression regulation of genes in cancer.

Authors:  Gauri A Patwardhan; Yong-Yu Liu
Journal:  Prog Lipid Res       Date:  2010-10-21       Impact factor: 16.195

2.  Low-density lipoprotein induced expression of connective tissue growth factor via transactivation of sphingosine 1-phosphate receptors in mesangial cells.

Authors:  Hesham M El-Shewy; Mimi Sohn; Parker Wilson; Mi Hye Lee; Samar M Hammad; Louis M Luttrell; Ayad A Jaffa
Journal:  Mol Endocrinol       Date:  2012-03-15

3.  Wilms tumor-suppressing peptide inhibits proliferation and induces apoptosis of Wilms tumor cells in vitro and in vivo.

Authors:  Wei Zhao; Juan Li; Ping Li; Fei Guo; Pengfei Gao; Junjie Zhang; Zechen Yan; Lei Wang; Da Zhang; Pan Qin; Guoqiang Zhao; Jiaxiang Wang
Journal:  J Cancer Res Clin Oncol       Date:  2019-08-28       Impact factor: 4.553

Review 4.  Sphingolipid signaling and hematopoietic malignancies: to the rheostat and beyond.

Authors:  Kenneth C Loh; Dianna Baldwin; Julie D Saba
Journal:  Anticancer Agents Med Chem       Date:  2011-11       Impact factor: 2.505

5.  Sphingolipid modulation of angiogenic factor expression in neuroblastoma.

Authors:  Mei-Hong Li; Timothy Hla; Fernando Ferrer
Journal:  Cancer Prev Res (Phila)       Date:  2011-05-16

6.  Antitumor Activity of a Novel Sphingosine-1-Phosphate 2 Antagonist, AB1, in Neuroblastoma.

Authors:  Mei-Hong Li; Rolf Swenson; Miriam Harel; Sampa Jana; Erik Stolarzewicz; Timothy Hla; Linda H Shapiro; Fernando Ferrer
Journal:  J Pharmacol Exp Ther       Date:  2015-06-23       Impact factor: 4.030

7.  Induction of chemokine (C-C motif) ligand 2 by sphingosine-1-phosphate signaling in neuroblastoma.

Authors:  Mei-Hong Li; Miriam Harel; Timothy Hla; Fernando Ferrer
Journal:  J Pediatr Surg       Date:  2014-05-16       Impact factor: 2.545

8.  FTY720 inhibits tumor growth and enhances the tumor-suppressive effect of topotecan in neuroblastoma by interfering with the sphingolipid signaling pathway.

Authors:  Mei-Hong Li; Timothy Hla; Fernando Ferrer
Journal:  Pediatr Blood Cancer       Date:  2013-05-23       Impact factor: 3.167

9.  Inhibition of connective tissue growth factor (CTGF/CCN2) in gallbladder cancer cells leads to decreased growth in vitro.

Authors:  Patricia Garcia; Pamela Leal; Carmen Ili; Priscilla Brebi; Hector Alvarez; Juan C Roa
Journal:  Int J Exp Pathol       Date:  2013-04-18       Impact factor: 1.925

Review 10.  Sphingosine-1-phosphate receptor 2.

Authors:  Mohamad Adada; Daniel Canals; Yusuf A Hannun; Lina M Obeid
Journal:  FEBS J       Date:  2013-08-19       Impact factor: 5.542

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.